ABSTRACT
Diabetic retinopathy (DR) is a complication of diabetes mellitus (DM) on the retina caused by uncontrolled high blood glucose levels in long term. Proliferative diabetic retinopathy (PDR) is the advanced form of DR characterized by the formation of new blood vessels in the retina which increases the risk of visual loss.
1, 2 Diabetic retinopathy is the most commonly found retinal vascular disorder in the Vitreoretina policlinic at Cipto Mangunkusumo Hospital. 3 In 2004-2009, there were 3988 DR visits and 38.3% of them were PDR. The percentage of PDR visits was increased to 47.9% in 2010-2012. 4 Damage to the structure of the retina as a result of long term hyperglycemia is the main pathogenesis of DR. PDR begins from retinal ischemia due to microvascular occlusion and retinal capillary nonperfusion .
It results in increased production of Vascular Endothelial Growth Factor (VEGF), which stimulates the formation of neovascularization. The new vessels are fragile and can lead to the buildup of lipoproteins and bleeding in the retina and vitreous. 5, 6 Research with therapy focusing on biomolecular activity is expected in order to prevent the pathological retinal response to hypoxia. 3, 7 Recent studies have shown that elevated HIF-1α and ICAM-1 levels affect the DR progression in PDR patients. 3, [8] [9] [10] [11] [12] [13] HIF-1α is a protein that plays a major role as a transcription factor in VEGF regulation, in which its accumulation was induced by retinal hypoxia.
3, 10, 13, 14 VEGF will increase retinal vascular permeability, microvascular occlusion, teleangiectasia, microaneurysms and retinal ischemia. Retinal ischemia leads to hypoxia that will stimulate the formation of HIF-1α, which in turn triggers more VEGF.
15, 16 ICAM-1 is an adhesion molecule that plays a role in inflammatory mechanisms of blood vessel's wall. Vascular Endothelial Growth Factor is known to corelate with ICAM-1 in the neovascularization process.
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METHODS
This study is a prospective, post-test only, open-labeled randomized clinical trial. The subjects of this study were 32 eyes of 32 PDR patients which were evaluated from January to November 2016 at Vitreoretina policlinic of Cipto Mangunkusumo Hospital. Subjects were divided into two groups, each group consisted of 16 subjects. The control group was treated with vitrectomy only, whereas bevacizumab group received IVB injection 1-2 weeks prior to vitrectomy. Inclusion criterias were DM patients aged more than 18 years, with vitreomacular traction or nonclearing vitreous haemmorhage, who are willing to participate in the study, and with signed informed consent. Patients with a previous history of vitrectomy surgery, intravitreal anti-VEGF or laser photocoagulation, and patients without central macular thickness (CMT) measurement before vitrectomy were excluded from this study. A volume of 0.5-1 mL vitreous sample was retrieved with 1 mL syringe connected to vitrectomy cutter before running intravenous fluids during vitrectomy. The level of HbA1c, duration of diabetes, and initial CMT were higher in the IVB group, but these differences were not statistically significant (p> 0.05) There is no statistically significant difference in CMT measurement between two groups at every measurement time (p> 0.05). The decrease of the CMT between pre-IVB injection (baseline) and post IVB injection (pre-vitrectomy) was statistically significant (p <0.002).
RESULTS
. Scattered diagrams at figure 1 and 2 above shows that there were no correlations between HIF-1α and ICAM-1 on CMT value prior to vitrectomy in both groups. The subject of this research consists of PDR patients with vitreomacular traction on most subjects, so this might affect the value of CMT in this study. Statistical tests were conducted in 26 subjects (14 control group and 12 IVB group) who had a complete VA data at every follow-ups. Table 5 : Visual acuity in both groups at baseline, prior to vitrectomy and at 2, 4, and 12 weeks post-operation
*Anova 2 way with General Linear Model
Only 26 subjects had a complete data of VA at all followups period and were included for the VA analysis, 14 from the control group and 12 from the IVB group. Postoperative VA in the IVB group was worse than in the control group at all measured time frames. These differences in VA between the two groups were statistically significant.
Post-operative complications appeared to be almost equal in proportion between the two groups. Postoperative vitreous hemorrhage in IVB group was found in subjects without silicone oil. Hyphema occured in the control group with poor blood pressure and blood sugar control (HbA1c: 11mg/dl). 
DISCUSSION
This study shows that the difference between the levels of HIF-1α and ICAM-1 in both groups is not statistically significant (p> 0.05). These results might be influenced by several factors such as the baseline levels of HIF-1α and ICAM-1, inadequate decreased of VEGF level in the IVB group, or a change in inflammatory mediators after IVB injection. Decreased levels of HIF-1α and ICAM-1 could not be seen if the baseline levels were higher in the IVB group. However in this study, the measurement of HIF-1α and ICAM-1 before vitrectomy could not be obtained.
Anti-VEGF binds to VEGF molecules, hence, preventing the VEGF to bind to its receptors. Bevacizumab works by holding on to all isoforms of VEGF-A. It has a longer halflife time and higher molecular weight than ranibizumab. 20 , 21 Victor et al 22 reported that PDR patients who had an IVB injection prior to vitrectomy had twice as low VEGF levels than the group that did not receive IVB.
Han et al 23 studied the effects of IVB injection 6 days prior to vitrectomy to the level of HIF-1α through immunohistochemical examination of the fibrovascular membrane obtained during vitrectomy. Expression of HIF-1α in DR group that had been given IVB injection was found to be lower than that of the control group. The subjects in the study were PDR with vitreous hemmorhage, traction, or macular edema. However, some patients in the study group also received laser photocoagulation before vitrectomy. Han et al 32 also discovered that laser photocoagulation prior to vitrectomy, prevents further ischemia and decreases the HIF-1α concentration.
Inadequate reduction of VEGF level in the IVB group could also affect the HIF-1α result in the IVB group. Victor et al 22 report that the lowest levels of VEGF found in the group that received a combination of laser photocoagulation and IVB injection. The levels of VEGF in the combination therapy were found to be 5 times lower compared to the control group. The similar HIF-1α levels between the case and the control group could be caused by the severe PDR subjects who require laser photocoagulation and IVB combination therapy, to achieve a significant ischemia inhibition effect to reduce levels of HIF-1α.
Another factor that can contribute to the rising HIF-1α concentration in this study is the change in inflammatory mediators after the IVB injection. An increased inflammatory mediator is a response from VEGF blockade, but the details are not completely understood. Some researchers reported inflammatory mediators change after IVB injection. 24, 25 Forooghian et al 25 reported a significant increase in inflammatory mediators such as IL-8 and TGF-β2 in the aqueous humor of PDR patients at 10 days after IVB administration. Stilla et al 26 report the effects of inflammatory mediators on HIF-1α. In inflammation, Ang-II, thrombin, TGF-β2 (Transforming Growth Factor-β2), IL-1β (Interleukin-1β), TNF-α (Tumor Necrosis Factor-α), NF-κB, and other factors contribute to the accumulation of HIF-1α. Increased TGF-β2 is expected to affect the expression of HIF-1α in inflammatory processes. 26 ICAM-1 can be induced by other inflammatory mediators such as IL-1 and TNF-α, which can be induced by TGF-β. 27 Yan et al 28 reported the post-injection effect of ranibizumab on levels of ICAM-1 for before and after 7 days. The study reported that the level of ICAM-1 in the group injected with ranibizumab one week prior to vitrectomy was higher than the control group. In the group who received ranibizumab injection for more than 1 week before vitrectomy, the level of ICAM-1 was lower than the control group. These results demonstrate that administration of intravitreal anti-VEGF can increase the ICAM-1 concentration in the initial period. However, our study uses bevacizumab which is a heavier Anti VEGF molecule, and persist for a longer periode in the vitreous when compared to ranibizumab. Hence, the inflammation effect after IVB is expected to last longer than that of ranibizumab.
HIF-1α affects the progression of macular edema in PDR. There was no correlation between the levels of HIF-1α and ICAM-1 on CMT prior to vitrectomy. CMT is affected by inflammation and also by vitreomacular traction of the fibrovascular membrane. The traction located at the optic disc area or along the vascular arcades will cause antero-posterior traction in the macular area. 29 The mean baseline VA in this study was 1.81 ± 0.36 in the control group and 1.93 ± 0.13 in the IVB group. The poor baseline VA in the IVB group might have certain effects on the also poor postoperative VA. This finding was similar to a study by Kaiser et al 30 that reported the patient with poor initial VA (logMAR> 1) have a settled VA within 1 year after vitrectomy. Abdelhakim et al 31 also found that VA in the subject with IVB injection 7 days prior to vitrectomy was not improved, even in patients with VA more than logMAR=1 or slightly better. The decrease in macular thickness happened in most of the subjects. This is consistent with a study by Arevalo 32 that found that intravitreal bevacizumab injections may have a beneficial effect on macular thickness and VA, even though CMT improvement is not always followed by VA improvement. 33 Recurrent vitreous hemorrhage occurred in three patients from IVB group without silicone oil tamponade. Yeung et al 34 reported that intraocular tamponade is more effective than IVB injection to prevent recurrent postoperative vitreous hemmorhage. Silicone oil has tamponade and compression effect on the blood vessels of the retina. Retinal redetachments occurred in two subjects, 1 subject in each group. It happened due to fibrovascular reproliferation or intraoperative atrophicretina-related retinal tears. 35 Hyphema was found in two subjects with glaucoma. It occurred in the control group who had poor blood sugar and blood pressure control.
This study is the first study that assesses both the vitreous levels of HIF-1α and ICAM-1 in PDR patients who received IVB injection. Baseline measurement of the HIF-1α and ICAM-1 levels are not possible is found to be limitations of this study. Greater number of subjects and examinations of other proinflammatory cytokines that may affect the levels of HIF-1α and ICAM-1 such as VEGF, interleukin, TNF-α, and TGF-β can be done in relation to this study.
CONCLUSION
The levels of HIF-1α and ICAM-1 in PDR patients do not decrease after one injection of intravitreal Bevacizumab 1-2 weeks prior to vitrectomy. The concentration of vitreous HIF-1α and ICAM-1 are not directly related to the CMT.
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